Windward Bio raised $165 million to fund clinical trials targeting respiratory disorders, expanding its portfolio in asthma, COPD, and additional potential indications. The funding supports at least one lead long-acting antibody program and a second asset positioned for respiratory and dermatological uses. The company’s stated strategy emphasizes dosing advantages versus existing biologic medicines, reflecting how antibody developers are competing on regimen convenience and sustained pharmacology in chronic inflammatory disease. The round signals continued investor appetite for late-preclinical and early clinical immunology platforms focused on respiratory and multi-indication biologic differentiation.